Bisphosphonate Use After Estrogen Receptor-Positive Breast Cancer and Risk of Contralateral Breast Cancer

J Natl Cancer Inst. 2011 Dec 7;103(23):1752-1760, GM Monsees, KE Malone, M-T Tang, PA Newcomb, CI Li

TAKE-HOME MESSAGE

Abstract

SUMMARY

OncologySTAT Editorial Team

For patients who survive breast cancer, current strategies for preventing a second primary breast cancer in the contralateral breast include adjuvant hormonal therapy and prophylactic contralateral mastectomy. A possible alternative approach is the use of bisphosphonates, which have shown promise in preventing primary breast cancer. Monsees et al, from the Fred Hutchinson Cancer Research Center, Seattle, report the first detailed population-based study to examine the association between bisphosphonate...

NOT A MEMBER?

Registration is FREE

  • Up-to-date oncology news
  • Journal article summaries
  • Commentaries and interviews
  • Drug and interactions database
  • Chemotherapy regimens
  • Daily e-newsletters

 

About Our Journal Scans

View a list of journals that the OncologySTAT editorial team scans every week in order to bring you the most practice-relevant original research and review articles.

Sign up for our newsletters

Too busy to follow cancer's top stories? Sign-up for 1 or more of our free newsletters -- delivered weekly to your inbox.

Cancer Type

  • Bladder
  • Bone
  • Breast
  • Breast (ER-Positive)
  • CNS/Brain
  • Colon and Rectum
  • Endocrine System
  • Esophagus
  • GYN (Non-Ovary)
  • GYN (Ovary)
  • Head and Neck
  • Hodgkin's Lymphoma
  • Kidney (Renal Cell)
  • Leukemia
  • Liver and Bile Duct
  • Lung
  • Multiple Myeloma
  • Myelodysplastic Syndrome
  • Myeloproliferative Diseases
  • Non-Hodgkin's Lymphoma
  • Pancreas
  • Pediatric Cancers
  • Prostate
  • Rare Cancers
  • Skin
  • Soft-Tissue Sarcoma
  • Stomach
  • Testicle
  • Forgot your password?
    Not a member? Free registration